Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Anders Österborg, Martin J.S. Dyer, Donald Bunjes et al. · Journal of Clinical Oncology · 1997 · 517 citations

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

James M. Foran, A. Z. S. Rohatiner, David Cunningham et al. · Journal of Clinical Oncology · 2000 · 471 citations

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Lawrence D. Piro, Christine A. White, A.J. Grillo-López et al. · Annals of Oncology · 1999 · 368 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +6

Treatment of Waldenström’s Macroglobulinemia With Rituximab

Meletios Α. Dimopoulos, Constantinos Zervas, Athanassios Zomas et al. · Journal of Clinical Oncology · 2002 · 254 citations